SPOTLIGHT: Committee backs Via trials


Shares of Via Pharmaceuticals jumped this morning after a monitoring committee endorsed safety and efficacy data for two mid-stage trials of VIA-2291, its lead therapy for cardiovascular disease. Top-line results are expected next year. Release